Pfizer tests heart drug safety in healthy volunteers
NCT ID NCT07455240
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how a new medicine, PF-07328948, is handled by the body and whether it is safe in healthy Chinese adults. Ten participants took the drug daily for a week. The goal was to gather early safety and drug-level information to support future heart failure treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, 101100, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does drug particle size matter? a study puts prifetrastat to the test
- Smoking may weaken dental fillings, new study suggests
- Pfizer tests drug interaction in tiny early study
- Can a drug and probiotic combo turn back the clock on aging?
- Pfizer checks if new atirmociclib tablet matches the old one
- Ibuzatrelvir drug study in healthy chinese volunteers completed